Abatacept
| Evidence Level: L3 | Predicted Indications: 7 |
Table of Contents
- Abatacept
- Pharmacist Assessment Report
- Abatacept: T-cell co-stimulation blocker (biologic) → Ankylosing Spondylitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Abatacept: T-cell co-stimulation blocker (biologic) → Ankylosing Spondylitis
One-Sentence Summary
Abatacept is a biologic fusion protein that blocks T-cell co-stimulation and is marketed in Canada as ORENCIA. The TxGNN model predicts it may be useful for ankylosing spondylitis. Support is limited: 1 small open-label Phase 2 pilot trial (n=30), 1 open-label pilot publication and several reviews, some of which describe T-cell-targeted biologics as ineffective in axial disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ankylosing spondylitis |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Abatacept is known to block T-cell co-stimulation, and ankylosing spondylitis is an immune-mediated inflammatory disease in which T-cell pathways could plausibly play a role. This is the basis for the model’s prediction.
The clinical picture is less supportive than the score suggests. The only abatacept-specific trial in this disease is a small, uncontrolled, open-label pilot. One review notes that non-TNF biologics targeting IL-1, IL-6 and T cells (abatacept) were not effective in axial spondyloarthritis, whereas TNF blockers are highly effective. TNF and IL-17 inhibitors are the preferred biologic options. The high score therefore reflects a plausible mechanism, not demonstrated efficacy.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00558506 | Phase 2 | Unknown | 30 | Open-label pilot of intravenous abatacept in ankylosing spondylitis, treating up to week 30; the only trial directly testing the drug in this disease |
| NCT01965132 | N/A | Recruiting | 10,000 | Korean nationwide registry of patients on biologics and targeted DMARDs, including ankylosing spondylitis; observational safety registry, not abatacept-specific |
| NCT07138898 | Phase 2 | Recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients having shoulder replacement; does not address efficacy in this disease |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21415053 | 2011 | Open-label pilot study | Ann Rheum Dis | 24-week pilot exploring short-term efficacy and safety of abatacept in active ankylosing spondylitis |
| 27856659 | 2016 | Review | Rheumatology (Oxford) | TNF blockers are highly effective in axial spondyloarthritis; non-TNF biologics including abatacept are described as not effective |
| 25488787 | 2014 | Review | Best Pract Res Clin Rheumatol | Overview of spondyloarthritis treatment beyond TNF-alpha blockade |
| 31171316 | 2018 | Review | Best Pract Res Clin Rheumatol | Emerging options in spondyloarthritis; TNF inhibitors were the only option for non-responders to NSAIDs for about 15 years until IL-17A inhibitors |
| 29278210 | 2017 | Review | Curr Pharm Biotechnol | Biologics in inflammatory arthritis, including ankylosing spondylitis |
| 18251219 | 2008 | Review | Rev Med Suisse | Rheumatology highlights of 2007; anti-TNF agents remain the agents of choice in ankylosing spondylitis |
| 21624184 | 2011 | Review | Arthritis Res Ther | New targeted therapeutics across inflammatory arthritides |
| 20959960 | 2011 | Review | Osteoporos Int | Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis |
| 26968522 | 2016 | Review | Pediatr Rheumatol Online J | Biologic agents in juvenile spondyloarthropathies |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02282097 | ORENCIA | Not recorded | Not recorded in local data |
| 02402475 | ORENCIA | Not recorded | Not recorded in local data |
Safety Considerations
Warnings and contraindications from the Canadian product label were not available in the data compiled for this report; please refer to the package insert.
- Drug Interactions: 73 interactions were recorded. Major-level interactions include:
- adalimumab
- baricitinib
- certolizumab pegol
- live BCG vaccine
Moderate-level interactions include other immunomodulating biologics (anakinra, canakinumab, alefacept, alemtuzumab), azathioprine, roflumilast and several live or attenuated vaccines. Zinc salts are minor. Combining abatacept with other immunosuppressants and giving live vaccines require particular caution.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible, but the only direct evidence is a small, uncontrolled pilot (one trial of unknown status plus one open-label publication). Reviews describe T-cell-targeted biologics as ineffective in axial disease, and TNF and IL-17 inhibitors remain preferred. The high model score alone does not justify advancing.
To proceed, the following is needed:
- Full results of the open-label pilot (NCT00558506 and PMID 21415053), including the size of the effect
- A randomized, placebo-controlled trial, or a justification for why it would succeed where reviews report lack of efficacy
- Mechanism-of-action data and Canadian label warnings and contraindications
- A comparison against TNF and IL-17 inhibitors, which are preferred therapies, and a plan for immunosuppression-related infection risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.